Monday, March 10, 2025 7:30:48 PM
zero82,
Thanks for reposting that again 😶
Yes, “relentless execution” …
✅️ She executed her plan to acquire, develop, and secure a valuable patent-fortified manufacturing technology called EDEN. (Flaskworks strategic acquisition was relatively recent in 2020).
✅️ She executed her plan to get a prestigious and reputable medical journal to publish an independently peer-reviewed analysis of the P3.
✅️ She executed her plan to acquire the commercial rights to ANOTHER patent-fortified novel dendritic cell technology that’s in PII trials funded by the U.S. DoD at Roswell Park.
✅️ She executed her plan to recruit Linda Liau to join the SAB at NWBO.
✅️ She executed her plan to secure a PIP approval and an MIA approval from MHRA followed by a voluminous MAA submission.
✅️ She executed her plan to recruit Dr. Ashkan to run the DCVax-L trial in Europe and lead the UK Specials Program that has the ongoing support of the MHRA.
“His work on brain cancer vaccines received the top presentation award by the British Neuro-Oncology Society in 2022 and promises to impact the care of patients with brain tumours worldwide.”
https://thejns.org/caselessons/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.xml
https://www.kcl.ac.uk/news/professor-keyoumars-ashkan-awarded-mbe-in-kings-new-years-honours
https://www.bbc.com/news/uk-england-london-66378288
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175903429
Thanks for reposting that again 😶
Yes, “relentless execution” …
✅️ She executed her plan to acquire, develop, and secure a valuable patent-fortified manufacturing technology called EDEN. (Flaskworks strategic acquisition was relatively recent in 2020).
✅️ She executed her plan to get a prestigious and reputable medical journal to publish an independently peer-reviewed analysis of the P3.
✅️ She executed her plan to acquire the commercial rights to ANOTHER patent-fortified novel dendritic cell technology that’s in PII trials funded by the U.S. DoD at Roswell Park.
✅️ She executed her plan to recruit Linda Liau to join the SAB at NWBO.
✅️ She executed her plan to secure a PIP approval and an MIA approval from MHRA followed by a voluminous MAA submission.
✅️ She executed her plan to recruit Dr. Ashkan to run the DCVax-L trial in Europe and lead the UK Specials Program that has the ongoing support of the MHRA.
“His work on brain cancer vaccines received the top presentation award by the British Neuro-Oncology Society in 2022 and promises to impact the care of patients with brain tumours worldwide.”
Consultant Neurosurgeon at @KingsCollegeNHS, Professor Keyoumars Ashkan, receives an MBE for services to neurosurgery.
— NHS London (@NHSEnglandLDN) December 31, 2024
In 2020, he removed patient Dagmar's brain tumour while she played her violin throughout the surgery. 👇pic.twitter.com/H2Z4LZic0h
https://thejns.org/caselessons/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.xml
https://www.kcl.ac.uk/news/professor-keyoumars-ashkan-awarded-mbe-in-kings-new-years-honours
https://www.bbc.com/news/uk-england-london-66378288
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175903429
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
